COMPARISON OF DISEASE STATUS AND OUTCOMES OF PATIENTS WITH RHEUMATOID ARTHRITIS (RA) RECEIVING ADALIMUMAB OR ETANERCEPT MONOTHERAPY IN THE UNITED STATES (US)

被引：0
|
作者：
Narayanan, S. [1 ]
Lu, Y. [2 ]
Hutchings, R. [2 ]
Baynton, E. [2 ]
机构：
[1] Ipsos Healthcare, Columbia, MD USA
[2] Ipsos Healthcare, London, England
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 03期
关键词：
D O I：
10.1016/j.jval.2015.03.898
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PMS13
引用
收藏
页码：A154 / A1555
页数：4
相关论文
共 50 条
  • [1] COMPARISON OF DISEASE STATUS AND OUTCOMES OF PATIENTS WITH RHEUMATOID ARTHRITIS (RA) RECEIVING ADALIMUMAB OR ETANERCEPT MONOTHERAPY IN EUROPE
    Narayanan, S.
    Lu, Y.
    Hutchings, R.
    Baynton, E.
    Hautamaki, E.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : 374 - 374
  • [2] COMPARISON OF DISEASE STATUS AND OUTCOMES OF PATIENTS WITH ANKYLOSING SPONDYLITIS (AS) RECEIVING ADALIMUMAB OR ETANERCEPT MONOTHERAPY IN THE UNITED STATES (US)
    Narayanan, S.
    Lu, Y.
    Hutchings, R.
    Graham, C. M.
    Baynton, E.
    [J]. VALUE IN HEALTH, 2015, 18 (03) : A292 - A293
  • [3] COMPARISON OF DISEASE STATUS AND OUTCOMES OF PATIENTS WITH PSORIATIC ARTHRITIS (PSA) RECEIVING ADALIMUMAB OR ETANERCEPT MONOTHERAPY IN EUROPE
    Narayanan, S.
    Lu, Y.
    Hutchings, R.
    Baynton, E.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A373 - A373
  • [4] COMPARISON OF DISEASE STATUS AND OUTCOMES OF PATIENTS WITH ANKYLOSING SPONDYLITIS (AS) RECEIVING ADALIMUMAB OR ETANERCEPT MONOTHERAPY IN EUROPE
    Narayanan, S.
    Lu, Y.
    Hutchings, R.
    Baynton, E.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A522 - A523
  • [5] Outcomes in Patients with Rheumatoid Arthritis Initiating Monotherapy with Etanercept, Adalimumab, or Janus Kinase Inhibitors
    Pappas, Dimitrios
    O'Brien, Jacqueline
    Kelleman, Mike
    Guo, Lin
    Shan, Ying
    Baker, Joshua
    Kricorian, Greg
    Stryker, Scott
    Collier, David
    [J]. ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 2798 - 2800
  • [6] COMPARISON OF CLINICAL CHARACTERISTICS OF PATIENTS WITH RHEUMATOID ARTHRITIS (RA) RECEIVING A BIOLOGIC MONOTHERAPY AND BIOLOGIC COMBINATION THERAPY IN THE UNITED STATES
    Narayanan, S.
    Lu, Y.
    Hutchings, R.
    Baynton, E.
    [J]. VALUE IN HEALTH, 2014, 17 (03) : A55 - A55
  • [7] COMPARISON OF PATIENTS WITH RHEUMATOID ARTHRITIS (RA) ON DISEASE REMISSION IN THE EUROPEAN UNION (EU) AND UNITED STATES (US)
    Narayanan, S.
    Lu, Y.
    Hutchings, R.
    Baskett, A.
    [J]. VALUE IN HEALTH, 2015, 18 (03) : A167 - A167
  • [8] COMPARISON OF REFILL GAP ANALYSIS METHODOLOGIES IN A POPULATION OF PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING ADALIMUMAB OR ETANERCEPT
    Carter, C.
    Bolge, S.
    Ingham, M.
    Schmeichel-Mueller, C.
    [J]. VALUE IN HEALTH, 2011, 14 (03) : A8 - A8
  • [9] COMPARISON OF DISEASE STATUS, TREATMENTS AND OUTCOMES OF PATIENTS WITH PSORIATIC ARTHRITIS RECEIVING THEIR FIRST BIOLOGIC IN THE EUROPEAN UNION AND UNITED STATES
    Narayanan, S.
    Baskett, A.
    Lu, Y.
    Hutchings, R.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A571 - A571
  • [10] Adalimumab (HUMIRA®) monotherapy significantly improves fatigue in patients with severe rheumatoid arthritis (RA)
    Dietz, BM
    Sterz, R
    Holtbrügge, W
    Kupper, H
    Van de Putte, LBA
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 392 - +
12345